Non-alcoholic Steatohepatitis (NASH) Treatment Market Size & Share, by Drug Type (Vitamin E, Pioglitazone, Obeticholic Acid, Lanifibranor, Semaglutide, Resmetirom, Aramchol); Distribution Channel (Hospital Pharmacies, Retail & Specialty Pharmacies) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

  • Report ID: 4695
  • Published Date: Aug 09, 2023
  • Report Format: PDF, PPT


Companies Dominating the Non-alcoholic Steatohepatitis Treatment Landscape

    • Intercept Pharmaceuticals, Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Pfizer, Inc.
    • Inventiva
    • Galmed Pharmaceuticals Ltd.
    • Novo Nordisk A/S
    • Madrigal Pharmaceuticals
    • Galectin Therapeutics
    • NGM Biopharmaceuticals
    • Brsitol-Myers Squibb Company
    • Can Fite
    • Zydus Lifesciences Ltd.
    • Mitsubishi Chemical Group Corporation

Browse Key Market Insights with Data Illustration:


In The News

  • Novo Nordisk A/S announced the extension of their collaboration with Gilead Sciences, Inc. for clinical trials in non-alcoholic steatohepatitis (NASH). The companies plans to carry out a phase 2b double-blind, placebo-controlled study to examine the safety and effectiveness of semaglutide, a GLP-1 receptor agonist from Novo Nordisk, and a fixed-dose combination of cilofexor, an investigational FXR agonist, and firsocostat, an investigational ACC inhibitor.
  • Pfizer, Inc. announces the fast track designation grant from U.S. Food and Drug Administration (FDA) to company’s investigational combination medication for the treatment of non-alcoholic steatohepatitis (NASH) and liver fibrosis. This will speed up the review process and make it easier to create new medications and vaccines that are meant to treat or prevent serious illnesses and meet unmet medical needs.

Author Credits:  Radhika Gupta, Shivam Bhutani

  • Report ID: 4695
  • Published Date: Aug 09, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Increasing incidences of NAFLD is the major factor driving the market growth.

The market size of non-alcoholic steatohepatitis treatment is anticipated to attain a CAGR of 18% over the forecast period, i.e., 2023 – 2035.

The major players in the market are Pfizer, Inc., Inventiva, Galmed Pharmaceuticals Ltd., Novo Nordisk A/S, Madrigal Pharmaceuticals, Galectin Therapeutics, NGM Biopharmaceuticals, Brsitol-Myers Squibb Company, Can Fite, Zydus Lifesciences Ltd., Mitsubishi Chemical Group Corporation, and others.

The vitamin E and pioglitazone segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.

The market in the North America region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.
Inquiry Before Buying Request Free Sample

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying